EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lung cancer organoids: models for preclinical research and precision medicine

Yajing Liu, Yanbing Zhou, Pu Chen

Frontiers in Oncology · 24.10.2023 · 13

DOI: 10.3389/fonc.2023.1293441 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 24.10.2023. Verfasst von Yajing Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Qingdao University, Qingdao, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is a malignancy with high incidence and mortality rates globally, and it has a 5-year survival rate of only 10%–20%. The significant heterogeneity in clinical presentation, histological features, multi-omics findings, and drug sensitivity among different lung cancer patients necessitate the development of personalized treatment strategies. The current precision medicine for lung cancer, primarily based on pathological and genomic multi-omics testing, fails to meet the needs of patients with clinically refractory lung cancer. Lung cancer organoids (LCOs) are derived from tumor cells within tumor tissues and are generated through three-dimensional tissue culture, enabling them to faithfully recapitulate in vivo tumor characteristics and heterogeneity. The establishment of a series of LCOs biobanks offers promising platforms for efficient screening and identification of novel targets for anti-tumor drug discovery. Moreover, LCOs provide supplementary decision-making factors to enhance the current precision medicine for lung cancer, thereby addressing the limitations associated with pathology-guided approaches in managing refractory lung cancer. This article presents a comprehensive review on the construction methods and potential applications of LCOs in both preclinical and clinical research. It highlights the significance of LCOs in biomarker exploration, drug resistance investigation, target identification, clinical precision drug screening, as well as microfluidic technology-based high-throughput drug screening strategies. Additionally, it discusses the current limitations and future prospects of this field.

Schlagwörter

Stichwörter der Autor:innen

biobanksbiomarker explorationdrug screeninglung cancer organoidsprecision medicine

Autor:innen und Institutionen

  • School of Pharmacy, Qingdao University, Qingdao, China.
  • Research and Development Department, NanoPeptide (Qingdao) Biotechnology Ltd., Qingdao, China.
  • Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Department of Chemical Engineering and Waterloo Institute for Nanotechnology, University of Waterloo, Waterloo, ON, Canada.

Zitieren

APA

Liu, Y., Zhou, Y., & Chen, P. (2023). Lung cancer organoids: models for preclinical research and precision medicine. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1293441

Vancouver

Liu Y, Zhou Y, Chen P. Lung cancer organoids: models for preclinical research and precision medicine. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1293441

BibTeX
@article{Liu2023,
  author = {Liu, Yajing and Zhou, Yanbing and Chen, Pu},
  title = {Lung cancer organoids: models for preclinical research and precision medicine},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1293441}
}
Kostenlos starten →